In addition, Demcizumab (anti-Notch ligand, DLL4 antibody), OMP-52M51 (anti-Notch1 antibody), OMP-18R5 (anti-Wnt receptor, FZD monoclonal antibody) and BBI608 (inhibitor of Stat3 and β-catenin pathways) could be better therapeutic agents to combat melanoma [144] (Fig. 3). This evidence concerns the gene NOTCH1 and melanoma.